Inhibition of plasma kallikrein by a highly specific active site blocking antibody.
Kenniston, J.A., Faucette, R.R., Martik, D., Comeau, S.R., Lindberg, A.P., Kopacz, K.J., Conley, G.P., Chen, J., Viswanathan, M., Kastrapeli, N., Cosic, J., Mason, S., DiLeo, M., Abendroth, J., Kuzmic, P., Ladner, R.C., Edwards, T.E., TenHoor, C., Adelman, B.A., Nixon, A.E., Sexton, D.J.(2014) J Biol Chem 289: 23596-23608
- PubMed: 24970892 
- DOI: 10.1074/jbc.M114.569061
- Primary Citation of Related Structures:  
4OGX, 4OGY, 4PUB - PubMed Abstract: 
Plasma kallikrein (pKal) proteolytically cleaves high molecular weight kininogen to generate the potent vasodilator and the pro-inflammatory peptide, bradykinin. pKal activity is tightly regulated in healthy individuals by the serpin C1-inhibitor, but individuals with hereditary angioedema (HAE) are deficient in C1-inhibitor and consequently exhibit excessive bradykinin generation that in turn causes debilitating and potentially fatal swelling attacks ...